Additionally, small molecule inhibitors targeting ADRM1 directly may represent a novel beneficial therapy for 20q13-amplified ovarian cancer, and may act through altering regulation of multiple ovarian cancer targets including HSP90s, MNAT1 and respective cyclins, ST1A3 and hormone levels, and HAX1 and apoptosis. The gene discussed is SULT1A1; the disease is ovarian carcinoma.